TNFSF10 and gastric cancer: In addition, the treatment of TRAIL-resistant gastric cancer cells with the antineoplastic agent geldanamycin leads to an increase in the deltex1 levels and a concomitant decrease in the FLIPL levels, rendering these cells sensitive to TRAIL.